efonidipine has been researched along with Adrenocortical Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, K; Inada, Y; Isaka, T; Tajima, N; Takada, Y; Tojo, K | 1 |
| Ikeda, K; Saito, T; Tojo, K | 1 |
2 other study(ies) available for efonidipine and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aldosterone; Angiotensin II; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line, Tumor; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Humans; Nitrophenols; Organophosphorus Compounds; Potassium Chloride; Steroid 11-beta-Hydroxylase | 2009 |
Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells.
Topics: Adrenocortical Carcinoma; Angiotensin II; Bucladesine; Calcium Channel Blockers; Cell Line, Tumor; Dehydroepiandrosterone Sulfate; Dihydropyridines; Diltiazem; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Hydrocortisone; Nitrophenols; Organophosphorus Compounds; Phosphoproteins; RNA, Messenger; Verapamil | 2011 |